日光控股:董事會會議日期
Bawang International Swings to Profit in 2023
Bawang International (Group) Holding (HKG:1338) reported profit attributable to owners of 13.6 million yuan for the year ended Dec. 31, 2023, compared with a loss of 19.3 million yuan in the previous
霸王集團:二零二三年年報
中國金典集團:年度報告 2023
Hengan International (1044.HK): Steady growth in core business, new retail and e-commerce channels continue to expand
The company's business situation in 2023: In 2023, the company achieved main business revenue of 23.768 billion yuan, an increase of 5.09% over the previous year, and realized a net profit of 2,801 billion yuan to mother, an increase of 45.51% over the previous year. Core business
Pioneer Pharmaceutical Biotechnology (00399.HK): The placement agreement has expired
Gelonghui, April 19 | Pilot Pharmaceutical Biotechnology (00399.HK) announced that since the prerequisites contained in the placement agreement were not fully reached or satisfied before April 18, 2024, the placement agreement has expired and the placement matters will not proceed.